Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first ...

Unlike Zepbound and Mounjaro, which are injections, orforglipron is a pill that can be a more attractive option for patients looking to lose weight or to bring down their glucose levels.

Zepbound revenue soared from $175.8 million to $1.9 billion, while Mounjaro sales jumped 60% to $3.5 billion.

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Michael Headrick says he’s lost 18 pounds since starting Zepbound injections about a month ago, with no noticeable side effects. (Photo courtesy of Adam Seif) Michael Headrick of Indianapolis ...

Despite these rapid growth rates, sales for Mounjaro and Zepbound fell well short of initial analyst predictions. Estimates for this earnings release were reset after the firm released a ...